Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Science from our Sisters

Staff  |  Issue: May 2007  |  May 1, 2007

Meningococcal C Vaccine Safe and Effective for Juvenile Arthritis Patients

Vaccination against meningococcal serogroup C (MenC) does not aggravate juvenile idiopathic arthritis (JIA), nor is the vaccine inhibited by immunosuppressive therapies, according to a study published in Arthritis & Rheumatism (2007;56:639-646).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For this multicenter cohort study, researchers followed 234 patients age one to 19 for six months before and six months after vaccination, with patients serving as their own controls. No significant increase in disease activity was seen in the six months after vaccination when compared with the six months preceding. Furthermore, a subgroup of 166 patients did not experience more relapses after vaccination—in fact, the relapse risk in the month after vaccination was smaller than in the other 11 months studied.

The group of patients had a strong immune response to the vaccine, with the average anti-MenC IgG geometric mean concentration increasing from 0.4 µg/ml before vaccination to 28.9 µg/ml after vaccination. This increase is similar to that seen in healthy children given the vaccine.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Some patients taking disease-modifying anti-rheumatic drugs, methotrexate, tumor necrosis factor-a blockers, and prednisone had reduced responses to the vaccine, but even these patients demonstrated adequate protection in a serum bactericidal antibody titer test.

“Patients with JIA can be vaccinated safely and effectively with the MenC conjugate,” wrote lead author Evelien Zonneveld-Huijssoon, MD, Wilhelmina Children’s Hospital at the University Medical Center Utrecht in The Netherlands, and colleagues. This was true even for patients receiving highly immunosuppressive medication.

National Look at Arthritis-related Work Disability

Almost a third of Americans with physician-diagnosed arthritis—about 6.8 million people—report that their condition affects their ability to work, according to a study published in Arthritis Care & Research (2007; 57(3):355-363).

For the study, the investigators analyzed data of 31,044 individuals between age 18 and 64 who completed the 2002 National Health Interview Survey (NHIS).

People with recurrent pain or an unknown income were more likely to report work limitations associated with arthritis, as were African Americans and Hispanics. Women, people with good or excellent health, and individuals with a college degree or income more than $20,000 reported arthritis significantly less frequently.

In contrast to some previous research, level of education—except for a college degree—did not correlate with arthritis disability, nor did insurance status.

The authors note several limitations to the study. The self-reported results are subject to the limitations of the respondent’s recall, and, in cases with multiple comorbidities, it can be difficult to identify the source of the disability. Furthermore, the NHIS did not distinguish between people unable to work because of arthritis and those whose work was limited by the condition, and the survey data provide no insight into whether the arthritis preceded the work limitations.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch Rheum Tagged with:ArthritisArthritis & RheumatologyArthritis Care & ResearchdisabilityJuvenile idiopathic arthritisResearch

Related Articles

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Adventures in Vaccinating

    April 17, 2021

    I’m a believer in blue light. I’ve spent years lecturing my insomniac patients, buzzed on prednisone, on the importance of good sleep hygiene. In my own home, I try to practice what I preach. When I’m ready for bed, I leave my laptop and phone on my nightstand, and concentrate on relaxing. If I can’t…

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences